Shanghai Fosun Pharmaceutical Group Co Ltd Reports Financial Results
Shanghai Fosun Pharmaceutical Group Co Ltd, a health care company based in China, has released its financial results for the current period.
- Net profit increased by 38.96% year-on-year to 17.02 billion yuan.
- Operating cash flow grew by 11.90% year-on-year to 21.34 billion yuan.
Revenue Growth
The company’s innovation-driven strategy has led to a notable increase in revenue from innovative pharmaceuticals, with a 14.26% year-on-year growth to 43 billion yuan.
Research and Development
Fosun’s focus on research and development has resulted in a 25.84 billion yuan investment in R&D, with a 16.51% ratio of R&D expenditure to pharmaceutical business income.
Stock Performance
Fosun’s stock price has shown a moderate increase, with a stable trend in recent months.